Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation

Bibliographic Details
Main Authors:	D Hartwell, J Jones, L Baxter, J Shepherd
Format:	Article
Language:	English
Published:	NIHR Journals Library 2011-04-01
Series:	Health Technology Assessment
Online Access:	https://doi.org/10.3310/hta15170

Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation
by: Hartwell, D., et al.
Published: (2011)

Chronic HCV treatment with peginterferon-ribavirin and severe tuberculosis re-activation
by: Calza Leonardo, et al.
Published: (2010-05-01)

Sustained virological response to treatment of chronic hepatitis C with peginterferon alfa and ribavirin
by: Junior André da Rosa, et al.
Published: (2012-06-01)

Individualizing HCV treatment with peginterferon and ribavirin: what needs to be done?
by: Donald M. Jensen
Published: (2009-01-01)

The clinical effectiveness and cost-effectiveness of peginterferon alfa and ribavirin for the treatment of chronic hepatitis C in children and young people: a systematic review and economic evaluation
by: Debbie Hartwell, et al.
Published: (2014-10-01)

Efficacy and safety of peginterferon alfa-2a and ribavirin treatment of chronic hepatitis C in the Republic of Serbia
by: Božić Milena, et al.
Published: (2012-01-01)

Cost effectiveness of peginterferon alfa-2B combined with ribavirin for the treatment of chronic hepatitis C in Brazil
by: Marcelo Cunio Machado Fonseca, et al.

The analysis of hepatitis C treatment with peginterferon alfa 2b and ribavirin in three regional hospitals in Taiwan
by: Wei-Hsin Ko, et al.
Published: (2006)

Early virologic response to сеpeginterferon alfa-2b in combination with ribavirin in treatment of patients with chronic hepatitis C
by: O. O. Znoyko, et al.
Published: (2014-09-01)

Danazol improves thrombocytopenia in HCV patients treated with peginterferon and ribavirin
by: Guillermo Cabrera Álvarez, et al.
Published: (2011-10-01)

Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial
by: Mario G. Pessôa, et al.
Published: (2012-01-01)

Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation
by: J Shepherd, et al.
Published: (2007-03-01)

Efficacy of daclatasvir plus peginterferon alfa and ribavirin for patients with chronic hepatitis C genotype 4 infection
by: Hussien Ahmed, et al.
Published: (2017-03-01)

Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection
by: Maribel Rodriguez-Torres, et al.
Published: (2016-11-01)

Peginterferon alfa-2a plus ribavirin for hemophilic patients with chronic hepatitis C virus infection in Taiwan
by: Jung-An Lin, et al.
Published: (2014-10-01)

Benefit of Treatment Individualization in Patients with Chronic Hepatitis C Receiving Peginterferon Alfa-2a and Ribavirin in a Large Noninterventional Cohort Study.
by: Wolf Peter Hofmann, et al.
Published: (2015-01-01)

Efficacy of triple therapy with thymalfasin, peginterferon α-2a, and ribavirin for the treatment of hispanic chronic HCV nonresponders
by: Jorge L. Poo, et al.
Published: (2008-10-01)

Treatment of anicteric acute hepatitis C with peginterferon alpha-2a plus ribavirin
by: Delić Dragan, et al.
Published: (2005-01-01)

Mycobacterium abscessus pulmonary infection during hepatitis C treatment with telaprevir, peginterferon and ribavirin
by: Alejandro Soza, M.D., et al.
Published: (2015-01-01)

Prediction of treatment week eight response & sustained virologic response in patients treated with boceprevir plus peginterferon alfa and ribavirin.
by: Alex Thompson, et al.
Published: (2014-01-01)

Review: Rapid virological response to peginterferon alfa and ribavirin treatment of chronic hepatitis C predicts sustained virological response and relapse in genotype 1 patients
by: Fred Poordad, et al.
Published: (2009-03-01)

The Predictive Factors for Favorable Outcomes of Peginterferon and Ribavirin Combination Therapy in HCV-Infected Patients
by: Javad Moayedi, et al.
Published: (2020-08-01)

A Randomized Study of Peginterferon Lambda-1a Compared to Peginterferon Alfa-2a in Combination with Ribavirin and Telaprevir in Patients with Genotype-1 Chronic Hepatitis C.
by: Robert Flisiak, et al.
Published: (2016-01-01)

Antinuclear antibody titer and treatment response to peginterferon plus ribavirin for chronic hepatitis C patients
by: Ming-Yen Hsieh, et al.
Published: (2012-02-01)

Regional differences in hepatitis C treatment with peginterferon and ribavirin in Japan: a retrospective cohort study
by: Ide K, et al.
Published: (2016-03-01)

High effectiveness of peginterferon alfa-2a plus ribavirin therapy in Korean patients with chronic hepatitis C in clinical practice
by: Nae-Yun Heo, et al.
Published: (2013-03-01)

Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review
by: J Shepherd, et al.
Published: (2000-12-01)

Overwhelming diffuse psoriasis during chronic HCV infection, after peginterferon-ribavirin treatment, supported by frequent resort to filgrastim rescue
by: Sergio Sabbatani, et al.

Curación de hepatitis crónica C con 12 semanas de tratamiento con peginterferón-alfa y ribavirina Healing of chronic hepatitis C following 12 week therapy with peginterferon-alpha and ribavirin
by: M. Barreales, et al.
Published: (2007-12-01)

Is peginterferon and ribavirin therapy effective in Korean patients with chronic hepatitis C?
by: Young Kul Jung, et al.
Published: (2013-03-01)

A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin.
by: Tarik Asselah, et al.
Published: (2016-01-01)

Grazoprevir/elbasvir in peginterferon alfa plus ribavirin experienced patients with chronic genotype 1 HCV/HIV co-infection: a non-randomized, open-label clinical trial
by: Lin YC, et al.
Published: (2019-04-01)

Peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy
by: E. Parise, et al.

Ribavirin plus interferon alfa in the treatment of chronic hepatitis C infection
by: Wen Hwang Chen, et al.
Published: (2000)

An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1).
by: Tarik Asselah, et al.
Published: (2016-01-01)

Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa
by: Liu CH, et al.
Published: (2014-04-01)

Antimitochondrial antibody serocoversion post-liver transplant during hepatitis C treatment with peginterferon α, ribavirin and telaprevir
by: Vladimir Marquez-Azalgara, et al.
Published: (2014-09-01)

A pilot study of add-on oral hypoglycemic agents in treatment-naïve genotype-1 chronic hepatitis C patients receiving peginterferon alfa-2b plus ribavirin
by: Ching-Sheng Hsu, et al.
Published: (2014-10-01)

The effectiveness of retreatment with peginterferon alfa and ribavirin in patients with chronic viral hepatitis C genotype 2 and 3: a prospective cohort study in Brazil
by: Artico Simara, et al.
Published: (2012-12-01)

Thalidomide with peginterferon alfa-2b and ribavirin in the treatment of non-responders genotype 1 chronic hepatitis C patients: proof of concept Talidomida, peginterferón alfa-2b y ribavirina en el tratamiento de pacientes no respondedores con hepatitis crónica C genotipo 1: estudio piloto
by: Benjamín Pardo-Yules, et al.
Published: (2011-12-01)

Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation

Similar Items

Similar Items